Noah Goodman

Kymera Therapeutics has appointed Noah Goodman as Chief Business Officer

Clinical-stage biopharma Kymera Therapeutics has announced the appointment Noah Goodman as its new Chief Business Officer.

Goodman brings extensive life sciences industry experience to the role, which he takes on after serving as President and Chief Business Officer of Chroma Medicine and nChroma Bio.

Prior to this, he was Executive Director, Business Development at Cadent Therapeutics, which was subsequently acquired by Novartis; and Director, Business Development and Strategy at Seres Therapeutics.

Goodman also worked in business development at Spark Therapeutics and served as a Management Consultant at Easton Associates earlier in his career.

Goodman said: “I’m thrilled to join the team during such an exciting time of growth and progress and look forward to realising the full potential and impact of our… portfolio.”

Also commenting on the appointment, Kymera’s Founder, President and Chief Executive Officer, Nello Mainolfi, said: “Noah’s demonstrated leadership and business acumen will support Kymera’s continued growth as we advance our expanding pipeline through clinical development and eventual commercialisation.”